ROCHE – WE INNOVATE HEALTHCARE. LET US INSPIRE YOUR CAREER.

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology.

We all dream of making a difference, improving people’s lives. At Roche, we have the resources, vision and passion to transform dreams into fulfilling careers.

We offer exciting career opportunities, both locally and internationally, within a culture that is supportive and rewarding. We value the contribution our employees make to Roche’s success, and we aim to create a work environment where feeling valued, respected and empowered is a daily experience.

Find out more about careers at Roche, http://careers.roche.com

Roche
We Innovate Healthcare
Letter from the President

Writing this second Editorial represents a suitable moment to have our traditional 'look back and forward' to important events in our European Federation for Medicinal Chemistry.

Let's start with some of the meetings that our Federation has sponsored this past year. The first one, the International Symposium on Advances in Synthetic and Medicinal Chemistry (ASMC), was jointly organized by the EFMC and ChemBridge Corporation with the sponsorship of ACS and held in St. Petersburg, Russia, from August 27 to 31, 2007. With more than 600 participants from 42 countries, this second edition of the ASMC has repeated the success of the first edition that was held in Moscow in 2004, thus confirming the validity of its formula, characterized by an unusual blend of avant-garde topics from the two sister disciplines of organic and medicinal chemistry. The successful outcome of this event is certainly due to the efforts of many people. Here I wish to thank, in particular Steve Ley (University of Cambridge) and Magid Abou-Gharbia (Wyeth Research), Gene Vaisberg and Sergey Altshteyn (ChemBridge Corporation), and Edmond Differding (UCB) for their invaluable contribution. It is my wish and that of all EFMC that this series of meetings will continue and we are looking forward to the 2009 Edition.

This year has also seen the launch of a new series of meetings to be organized jointly every two years by the ACS-Medi Division and EFMC in collaboration, each time, with the national society of a European country. The aim of this initiative is to bring together leading US and European medicinal chemists from academia and industry in a meeting intended to build collaborative bridges among the participants, while highlighting recent advances the drug discovery and the medicinal chemistry of chosen topics. The first of these meetings has been organized in Italy in collaboration with the Division of Medicinal Chemistry of the Italian Chemical Society and held in Siena, from October 7 to 9, 2007 in the spectacular venue of S. Maria della Scala under the title of Frontiers in CNS and Oncology Medicinal Chemistry. It has been a greatly successful meeting from both scientific and organisation points of view and I wish to thank here, in particular, Giovanni Gaviraghi (Siena Biotech) and Dave Rotella (ACS-Medi Division) for their key role in organizing a meeting that has seen 200 participants from 20 countries and has proven to be very successful from both a scientific and an organisation point of view. The second meeting is planned for the second half of 2009 and the first organisation details will shortly appear in the ACS and EFMC websites.

Let me remember, finally, the 5th Joint Meeting on Medicinal Chemistry (JMMC) held in June in Portorož, in the Slovenian Adriatic and organized in a splendid way by Daniel Kikelj. I again congratulate him and his collaborators for their successful achievement.

Among the events coming up for medicinal chemists in 2008, let me highlight here the XXth International Symposium on Medicinal Chemistry, EFMC-ISMC 2008 that will take place in Vienna from August 31 until September 4. Peter Ettmayer, together with the Organising Committee members, is
preparing what promises to be a new, very exciting edition in both scientific and social respects, of the most 'classical' among our symposia. For more information please have a look at www.ismc2008.org.

Among the key activities and the several events in which the EFMC has been involved during 2007 let me outline that during the Council held in June in Portorož we had the pleasure to welcome two new member organizations: the Section of Pharmaceutical/Medicinal Chemistry of the German Pharmaceutical Society and the Group of Medicinal Chemistry of the Portuguese Chemical Society. We look forward to a fruitful collaboration with both of them!

During this Council, moreover, there has been the report of the special Committee formed in order to revise and update the Federation regulations and bylaws. Among the revisions proposed and approved, the change in the composition of the Executive Committee, with a new, mandatory balance between Industry and Academia members, and the introduction in the Regulations of the recently formed Committees, seen as important, additional instruments for improving our organisation and management. I am sure, at this regard, that through the efforts of all our Committees chairs and members we will increasingly be able to focus on a mixing of the old and the new, on a blending of new ideas and memories towards our common goals of promotion, support and unity for the Federation.

Besides the introduction of the Committees a major breakthrough in our Federation has certainly been the publication of the first two issues of our newsletter ‘MedChemWatch’ through which the EC intends to communicate and inform our members on a regular basis. Besides this key achievement, I want to call again your attention on the website of our federation. All organized and sponsored events, call for nominations, awards, a complete list of functions of our Federation and the MedChemWatch issues can be viewed at www.efmc.info. It will be with your participation and support that our website will function as an effective hub of communication and information for and about our members, thus elevating the visibility of our federation.

The Federation presents several major Awards on a biennial basis. These are the Nauta Award for Pharmacology, the UCB-Ehrlich Award for Excellence in Medicinal Chemistry and the Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery. I would like to strongly encourage EFMC members to follow the call for nominations and to submit candidates for the Awards which will be conferred on the occasion of the XXth EFMC-ISMC in Vienna. You can have all the information regarding the Awards by consulting our website.

Our agenda for this and for the coming year is by no means final and we are always happy to hear ideas and proposals which may be incorporated into our activities. Please feel free, at this regard, to contact me or any of the Committee Chairs which are listed on our website. With everyone’s help I look forward to a new productive year creating experiences which will enhance our profession and our Federation.

December holidays are just ahead. I hope that they are filled with good health and happiness for each of you and your families.

Sincerely,

Roberto Pellicciari,
President, EFMC
Experts in Boron Chemistry

BOROCHEM
Immeuble Emergence
7, rue Alfred Kastler - 14000 Caen - France
Tél. +33 231 945 073 - Fax +33 231 462 651
info@borochem.fr - www.borochem.fr
Table of Content

01 Editorial
03 Corporate Members
05 Table of Content
07 Executive Committee 2008
08 Council
09 EFMC Objectives
10 Education and Training Committee
11 Initiatives Committee
12 Industry Liaison Committee
13 Information & Communication
16 EFMC Awards
19 Calendar of Events
25 Article
34 Austria
35 Belgium
38 Denmark
39 France
41 Germany
43 Greece
44 Hungary
45 Israël
46 Italy
47 Latvia
48 Poland
49 Portugal
50 Russia
51 Slovenia
52 Spain
54 Sweden
55 Switzerland
56 The Netherlands
57 Turkey
58 United Kingdom

60 Directory of companies

Reproduction:
All items published in this directory are protected by copyright. Reproduction by reprint, photocopy, microfilm or any other process is not allowed without the prior written permission of the publisher.

www.efmc.info
COMBINING INNOVATION AND EXPERIENCE

Johnson & Johnson
PHARMACEUTICAL RESEARCH & DEVELOPMENT
DIVISION OF JANSSEN PHARMACEUTICALS N.V.

Across the globe, around the clock, Johnson & Johnson Pharmaceutical Research & Development is committed to improving the lives of millions.

www.jnjpharmarnd.com
Executive Committee

President
Prof. Dr. Roberto PELLICCIARI
UNIVERSITY OF PERUGIA
Dipartimento di Chimica e Tecnologia del Farmaco
Via del Liceo 1
06123 Perugia Italy
Tel: +39 075 585 51 20 / +39 075 585 5164
Fax: +39 075 585 51 24
rp@unipg.it

President Elect
Prof. Dr. Gerhard ECKER
UNIVERSITY OF VIENNA
Department of Medicinal Chemistry
Althanstrasse 14
1090 Vienna Austria
Tel: +43 1 4277 55110
Fax: +43 1 4277 9551
gerhard.f.ecker@univie.ac.at

Secretary/Treasurer
Dr. Rasmus CLAUSEN
UNIVERSITY OF COPENHAGEN
Department of Medicinal Chemistry
Universitetsparken 2
2100 Copenhagen Denmark
Tel: +45-35336566
Fax: +45 35306040
rac@dfuni.dk

Member
Dr. David ALKER
The Biological and Medicinal Chemistry Sector (BMCS)
of the Royal Society of Chemistry (RSC) (President)
DAVID ALKER ASSOCIATES
19, Shakespeare Road, Birchington
CT7 9ET Kent United Kingdom
Tel: +44-1843-845-783
davidalker@btinternet.com

Member
Dr. Brigitte LESUR
INSTITUT DE RECHERCHES SERVIER
125, Chemin de Ronde
78290 Croissy sur Seine France
Tel: +33 1 55 72 26 16
Fax: +33 1 55 72 25 66
brigitte.lesur@fr.netgrs.com

Member
Prof. Dr. Péter MÁTYUS
Organic and Medicinal Chemistry Division (OMCD)
of the Hungarian Chemical Society (HCS) (President)
SEMMELEWEIS UNIVERSITY
Hőgyes E.u.7.
1092 Budapest Hungary
Tel: +36-1-2170-851
Fax: +36-1-2170-851
peter.matyus@szerves.sote.hu
Council

The Council consists of the members of the EC and one delegate of each Adhering Organisation. According to the new statutes, the voting rights are allotted according to the following rules: members of the EC: 1 vote, countries with up to 99 members: 2 votes, countries with 100-199 members: 3 votes, countries with 200-399 members: 4 votes, countries with 400-599 members: 5 votes, countries with 600-899 members: 6 votes, countries with more than 899 members: 7 votes. As for countries with more than one Adhering Organisation, votes will be proportionally distributed among them, taking into account their respective memberships. The resulting number will be rounded off to the closest digit.

Members:

**Dr. David Alker**, Executive Committee

**Dr. Richard Armer**, Oxagen Ltd
Society for Medicines Research, SMR, UK

**Prof. Koen Augustyns**, Universiteit Antwerpen
Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV), Belgium

**Dr. Derek Buckle**, DRB Associates
The Biological and Medical Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC), UK

**Dr. Edmond Differding**, UCB
Société Royale de Chimie (SRC), Medicinal Chemistry Division, Belgium

**Dr. Rasmus Clausen**, University of Copenhagen
Executive Committee

**Prof. Dr. Bernd Clement**, Universität Kiel
German Pharmaceutical Society, Section of Pharmaceutical/Medicinal Chemistry, Germany

**Prof. Gunars Duburs**, Latvian Institute of Organic Synthesis
Latvian Association for Medicinal Chemistry, Latvia

**Prof. Gerhard Ecker**, University of Vienna
Executive Committee

**Dr. Peter Ettmayer**, Boehringer Ingelheim Austria GmbH
Austrian Chemical Society, Medicinal Chemistry Section, Austria

**Dr. Marina Gordaliza**, Universidad de Salamanca
Sociedad Española de Química Terapéutica, Spain

**Dr. Anders Karlen**, Uppsala University
The Swedish Academy of Pharmaceutical Sciences, Section for Medicinal Chemistry, Sweden

**Prof. Katarzyna Kieć-Końkowicz**, Jagiellonian University, Medical College
Medicinal Chemistry Section of the Polish Chemical Society, Poland

**Prof. Danijel Kikelj**, University of Ljubljana
Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society, Slovenia

**Prof. Olivier Lafont**, Faculté de Médecine et de Pharmacie de Rouen
Société de Chimie Thérapeutique, France

**Dr. Brigitte Lesur**, Institut de Recherches Servier
Executive Committee

**Prof. Péter Mátyus**, Semmelweis University
Executive Committee

**Dr. Peter Mohr**, Hoffmann-La Roche AG
Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS), Switzerland

**Prof. Rui Moreira**, University of Lisbon
Group of Medicinal Chemistry of the Portuguese Chemical Society, Portugal

**Prof. Luisa Mosti**, University of Genova
Division of Medicinal Chemistry of the Italian Chemical Society (Società Chimica Italiana), Italy

**Prof. Roberto Pellicciari**, Universita di Perugia
Executive Committee

**Prof. M. Fethi Sahin**, Gazi University
Turkish Association of Medicinal and Pharmaceutical Chemistry, Turkey

**Prof. Gerd Schnorrenberg**, Boehringer Ingelheim Pharma KG
Division of Medicinal Chemistry of the German Chemical Society (GDCh), Germany

**Dr. Jeffrey Sterling**, TEVA Pharmaceutical Ind
The Medicinal Chemistry Section of the Israel Chemical Society, Israel

**Prof. Kristian Strømgaard**, The Danish University Of Pharmaceutical Sciences
The Danish Society for Pharmacology and Toxicology, Denmark

**Prof. Henk Timmerman**, Vrije Universiteit LACDR
Section of Pharmacochemistry, Royal Netherlands Chemical Society (KNCV), The Netherlands

**Assoc. Prof. Anna Tsantili-Kakoulidou**, University of Athens
Hellenic Society of Medicinal Chemistry, Greece

**Dr. János Wölfling**, University of Szeged
Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS), Hungary

**Prof. Nikolay S. Zefirov**, Moscow State University
The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section, Russia
The European Federation for Medicinal Chemistry (EFMC) is an independent association founded in 1970. Free from any political convictions, it represents the scientific organisations from 23 European countries and covers a geographical area the size of the USA with a similar scientific population. Its objective is to advance the science of Medicinal Chemistry by promoting cooperation and encouraging strong links between the National Adhering Organisations, in order to promote contacts and exchanges between medicinal chemists in Europe and around the World. Moreover, it offers medicinal chemists an opportunity to present their work internationally by organising the biennial International Symposium on Medicinal Chemistry (ISMC). These symposia, with an average attendance of 1,400 delegates, are highly international with a broad range of speakers and attendees representing well in excess of 40 countries.

The EFMC pursues its activities via the Executive Committee, the Council and 4 committees: Education and Training Committee, Industry Liaison Committee, European Commission R&D Initiatives Committee, and Information & Communication Committee.

These Committees strengthen the links between Council and EC and help to define the mission, vision and goals of EFMC.

The EFMC has very strong links with the Medicinal Chemistry Division of the American Chemical Society. The EFMC has a permanent representative at its management meetings and also has a permanent representative on the Long Range Planning Committee of the ACS Medicinal Chemistry Division. Through this collaboration the ACS convenes sessions for the biennial ISMC Symposia, and conversely the EFMC convenes sessions for ACS National meetings. This reciprocal relationship is continually strengthened and recently extended to the joint organisation of a bilateral meeting. Furthermore, the EFMC has a specific representative on the Editorial Advisory Board of the Journal of Medicinal Chemistry, thus demonstrating the quality of European science and its scientists. EFMC also has strong links with the European Federation for Pharmaceutical Sciences. Besides exchanging sessions at various scientific congresses, EFMC and EUFEPS joined forces in establishing an European Pharmaceutical Sciences Leadership Forum. In addition, the EFMC also collaborates with the Asian Federation of Medicinal Chemistry by participating in meetings organised by the AFMC and vice versa, giving the EFMC a broad international footprint.

An important part of the EFMC activities is sponsorship of national scientific meetings organised between two or more countries. Supported by Bentham, it also awards bursaries for younger scientists to attend ISMC meetings. The EFMC also acknowledges the excellence of medicinal chemists’ work, by conferring three major awards: the Nauta Award on Pharmacology, the UCB-Ehrlich Award for Excellence in Medicinal Chemistry and the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery, which are given every two years for outstanding achievements in the field of Medicinal Chemistry.

The EFMC homepage is now hot-wired to the web sites of many national organisations, thus facilitating the flow of information, and the yearbook “Medicinal Chemistry in Europe” should help to further develop cooperation between member organisations as well as their industrial partners and therefore advance medicinal chemistry in Europe, and by extension around the globe.
Committee Membership:

- Péter MÁTYUS – ETC Chair (EFMC Executive Committee member)
- Dave ALKER (EFMC Executive Committee member, Point Contact for EFMC Corporate Membership)
- Sylviane GIORGI-RENAULT (Member of SCT, France)
- Marina GORDALIZA (Council Member)
- Danijel KIKELJ (Council Member)
- Guiseppe RONSISVALLE (Council Member)
- Fehti SAHIN (Council Member)
- Henk TIMMERMAN (Council Member, EFMC Executive Committee Advisor)
- Anna TSANTILI (Council Member)

Committee Objective:
To ensure the training of the next generation of medicinal chemists within Europe at both the undergraduate and postgraduate levels, based on strong industry-academia cooperation, and to provide a platform to address future development training needs

Committee Goals:

- Undertake a comprehensive analysis of the structure and profile of European teaching and education systems for medicinal chemistry
- Agree the core skills a medicinal chemist should acquire during their Masters level and PhD level training
- Quantify existing undergraduate and postgraduate level training courses within Europe
- Identify best practice from this analysis and publish an overview and conclusions
- Summarise career destinations for Masters and PhD level medicinal chemists, and identify core skills gaps in each country from both the industrial and academic perspective
- Identify deficiencies in the current teaching and education of medicinal chemistry in Europe, and establish means of addressing these
- Summarise currently available software for e-learning of medicinal chemistry
- Continue to support the current residential postgraduate Medicinal Chemistry Schools (training courses) in Italy, the Netherlands and Switzerland
- Facilitate the establishment of additional local residential Medicinal Chemistry Schools in other European countries
- Incorporate medicinal chemistry trends in future Medicinal Chemistry Schools
- Include sessions on the teaching and education of medicinal chemistry on a regular basis in EFMC-sponsored symposia
- Hold a satellite session at each ISMC on the future trends and direction of medicinal chemistry
- Raise the awareness and importance of appropriate medicinal chemistry training and education with other relevant learned societies e.g. IUPAC, EUFEPS

In order to achieve these challenging goals the Education Committee would welcome your knowledge, experience and ideas. If you wish to contribute towards our objectives, please contact Peter Matyus at peter.matyus@szerves.sote.hu
European Commission R&D Initiatives Committee

Current committee membership:

- Ferran SANZ – Chair (Universitat Pompeu Fabra, Spain)
- Maria José CAMARASA (CSIC; President of Spanish Society of Medicinal Chemistry)
- Giovanni GAVIRAGHI (Siena Biotech, Italy)
- Peter ETTMAYER (EFMC Council Member, Austria)
- Katarzyna KIEC-KONONOWICZ (EFMC Council Member, Poland)
- Hans Peter MAERKI (Roche, Switzerland)
- Hans-Ulrich STILZ (Aventis; President of German Society of Medicinal Chemistry)
- Geoffrey STEMP (GlaxoSmithKline, UK)
- Nico VERMEULEN (Leiden Drug Research Center, The Netherlands)

Committee Objective:

To improve and strengthen the contacts of EFMC to the European Commission in order to increase the visibility of the EFMC and its activities. Main goal in the near future will be to provide information about the Innovative Medicines Initiative to the Member Societies and to establish a platform for communicating the strengths and needs of Medicinal Chemistry to the European Commission. In addition, the ECIC Committee will also act as a forum for discussing and promoting R&D initiatives important for Medicinal Chemistry in Europe.

Committee Goals:

- To strengthen and improve communication with the European Commission
- To support the National Adhering Organisations by ensuring that information on European R&D initiatives is communicated in an efficient and timely manner.
- To provide a platform for dissemination of activities related to the Innovative Medicines Initiative
- To communicate the strengths and needs of Medicinal Chemistry to the European Commission and other authorities
- To promote Medicinal Chemistry R&D initiatives throughout Europe

In order to achieve these challenging goals the committee is open to suggestions and comments. Please send your ideas to Ferran Sanz at fsanz@imim.es
Industry Liaison Committee

Current Committee Membership:

- Brigitte LESUR – ILC Chair (EFMC Executive Committee member)
- Dave ALKER (EFMC Executive Committee member, Point Contact for EFMC Corporate Membership)
- Henk TIMMERMAN (Council member, EFMC Executive Committee Advisor)
- Derek BUCKLE (Council member)

Committee Objective:

To promote and improve liaison and cooperation between EFMC and Industry so that the EFMC can better achieve its over-arching objective to advance the science of medicinal chemistry. This includes increasing the visibility of EFMC activities within companies which employ medicinal chemists as well as those related industries for whom medicinal chemistry is an enabling science or for whom medicinal chemists represent a significant customer base.

Committee Goals:

- To act as a link between industry and academia for the exchange of ideas, information and knowledge on medicinal chemistry
- To understand and champion the views of industry within EFMC and, where appropriate, to promote these on a wider, European stage
- To provide a forum for industrial and academic medicinal chemists to discuss the evolution of medicinal chemistry in Europe
- To promote opportunities for:
  - Short-term (up to 12 month) training periods in industry for students
  - Partnership/collaborative programmes in medicinal chemistry research topics
  - Industry/academia joint grants and sponsorship programmes
- Longer term to the committee to set up a system for job offers and candidate CV through the EFMC web-site
- Longer term to set up a directory of European centres of specific expertise in drug research

In order to achieve these challenging goals the ILC would welcome new committee members. If you are interested please contact either Brigitte Lesur blesur@hotmail.fr or Dave Alker dabidalker@btinternet.com
Information & Communication Committee

Current committee membership:

- Gerhard ECKER – ICC Chair (EFMC Executive Committee member, Austria)
- Koen AUGUSTYNS (University of Antwerp, Belgium)
- Erden BANOGLU (Gazi University, Turkey)
- Gabriele COSTANTINO (University of Perugia, Italy)
- Anders KARLEN (EFMC Council Member, Sweden)
- Olivier LAFONT (EFMC Council Member, France)
- Jordi MESTRES (Universitat Pompeu Fabra, Barcelona, Spain)
- Kristian STROMGAARD (EFMC Council Member, Denmark)

Committee Objective:

To improve and strengthen the communication to the EFMC member societies and individual Medicinal Chemists. The main goals are to increase the visibility of the EFMC and its activities via extensive use of internet-based technology and to establish an information platform for all issues related to Medicinal Chemistry in Europe. In addition, the ICC Committee will also support the other Committees in coordinating their activities and disseminating information.

Committee Goals:

- To edit and distribute MedChemWatch, the official e-Newlsetter of EFMC
- To explore possibilities for creating benefits for Corporate Members and individual Medicinal Chemists who are members of our National Adhering Organisations

In order to achieve these challenging goals the committee is open to suggestions and comments. Please send your ideas to Gerhard Ecker gerhard.f.ecker@univie.ac.at

MedChemWatch

The official EFMC e-newsletter
EFMC - ISMC 2008
XXTH INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY

Vienna, Austria - August 31 – September 4, 2008

Symposium Secretariat:
LD Organisation, Scientific Conference Producers
55, route de Blocy,
B-1348 Louvain-la-Neuve,
Belgium
Tel. +32 10 45 47 77
Fax: +32 10 45 97 19
secretariat@ismc2008.org

www.ismc2008.org

ORGANISING COMMITTEE

Chairman
Peter ETTMAYER
(Boehringer Ingelheim, Austria)

Members
Gerhard ECKER
(University of Vienna, Austria & EFMC)
Roberto PELLICCIARI
(University of Perugia, Italy & EFMC)
Feran SANZ
(University Pompeu Fabra, Spain)
Edmond DIFFERDING
(UCB, Belgium)
CONFIRMED PLENARY LECTURERS

Paul HERRLING
(Novartis International, Switzerland)

Chris DOBSON
(University of Cambridge, UK)

Barbara IMPERIALI
(Massachusetts Institute of Technology, USA)

Steven V. LEY
(University of Cambridge, UK)

Magid ABOU-GHARBIA
(Wyeth Research, USA)

GlaxoSmithKline Award
for Outstanding Achievement
in the Field of Chemical Biology

EFMC AWARD LECTURES

The Nauta Award for Pharmacology

The UCB-Ehrlich Award for
Excellence in Medicinal Chemistry

The Prous Institute–Overton
and Meyer Award for New Technologies
in Drug Discovery

EFMC - BENTHAM TRAVEL GRANTS

Travel grants (500 € each) are available for
10 young scientists, not older than 30 years,
who will be nominated by the EFMC-ISM C
2008 International Organising Committee.
Details for applications are available on the
symposium website.
Deadline for submission is April 10, 2008.

SESSIONS AND SESSION COORDINATORS

Novel Lead Finding Approaches
Hans-Ulrich STILZ (Sanofi-Aventis, Germany)

Chemistry Strategies to Reduce
Attrition in Drug Discovery
Geoffrey STEMP (GlaxoSmithKline, UK)

Emerging Drugs
Bernd RIEDL (Bayer Healthcare, Germany)

Kinase Selectivity–Is it Necessary? (ACS)
David ROTELLA (Wyeth Research, USA)

Predictive ADME/Tox Methods:
What to Apply When?
Scott BOYER (AstraZeneca, Sweden)

Macromolecular and Polymeric Drugs
Abraham J. DOMB
(Hebrew University of Jerusalem, Israel)

Fragment–Based Drug Discovery (ACS)
Jeffrey ALBERT (AstraZeneca, USA)

Imaging Ligands and Biomarkers (EuFEPS)
Pia VUORELA (Åbo Akademi University, Finland)

Natural Products as Starting Points
in Drug Discovery
Erdem BANOGLU (Gazi University, Turkey)

Novel Approaches for treatment
of Neurodegenerative Diseases
Magid ABOU-GHARBIA (Wyeth Research, USA)

Type 2 Diabetes: The Incretin System
Koen AUGUSTYN
(University of Antwerp, Belgium)

Progress in COPD and Asthma Therapy
Matthias GRAUER
(Boehringer Ingelheim, Germany)

Allosteric Modulation
and GPCR Drug Discovery
Rob LEURS (VU University Amsterdam,
The Netherlands)

Oncology
Graham WARRELLOW (UCB SA, UK)

Immunology & Immunomodulation
Katerina LEFTHERIS
(Bristol–Myers Squibb, USA)

Antipsychotic Targets
Klaus P. BØGEESO (H. Lundbeck, Denmark)

Antivirals
Maria Jose CAMARASA (SEGT, Spain)

Pain
Mark DUGGAN (Amgen, USA)

Exploring the Chemical Space
Herbert WALDMANN (Max Planck Institute
of Molecular Physiology, Germany)

Stefan WETZEL (Max Planck Institute
of Molecular Physiology, Germany)

Chemokines
Gerhard ECKER (University of Vienna, Austria)

Systems Level Research: Rnsorm Drug Target
Identification and Therapy Design
Harel WEINSTEIN (Cornell University, USA)

New Computational Approaches
Supporting Drug Design
Jordi MESTRES (IMIM and
Universitat Pompeu Fabra, Spain)

Druggability of Protein–Protein Interactions
Peter NUSSBAUMER (Novartis, Austria)

Systems Biology & Medicinal Chemistry
Christian NOE (University of Vienna, Austria)

Structure Based Drug Design (AFMC)
Esin AKI-SENER (Ankara University, Turkey)

Modulators of Adenosine and P2Y Receptors
Kenneth A. JACOBSON (NIDDK, USA)

Addressing Therapeutic Complexity in Oncology
with Medicinal Chemistry
Graeme ROBERTSON (Siena Biotech, Italy)
EFMC 2008 AWARDS

Call for nominations

DEADLINE: JANUARY 31, 2008

Nominations for these Awards consist of a nomination letter, a brief CV, including a list of selected publications and two supporting letters. The nominations should be submitted to the Chairman of the Juries, Professor Roberto Pellicciari, President of EFMC, Dipartimento di Chimica e Tecnologia del Farmaco, via del Liceo 1, 06123 Perugia, Italy.
FAX: +39 075 5855124 E-MAIL: EFMCawards@efmc.info
THE NAUTA AWARD
FOR PHARMAOCHEMISTRY

For the advancement of medicinal chemistry and the development of international organizational structures in Medicinal Chemistry. The Award will be given for outstanding achievements in the field of Medicinal Chemistry.

THE UCB-EHRlich AWARD
FOR EXCELLENCE IN MEDICINAL CHEMISTRY

To acknowledge and recognise outstanding research in the field of Medicinal Chemistry in its broadest sense by a young scientist. This Award has been established with the support of UCB Pharma.

THE PROUS INSTITUTE-OVERTON AND MEYER AWARD
FOR NEW TECHNOLOGIES IN DRUG DISCOVERY

To encourage innovation and investigation in technological development related to drug discovery, this Award established with the support of Prous Institute will be given for the discovery, evaluation or use of new technologies.

The Awards will be conferred on the occasion of the XXth EFMC ‘International Symposium on Medicinal Chemistry’ (ISMC) to be held in Vienna, Austria, 31st August to 4th September, 2008
Bioorganic & Medicinal Chemistry
- The Tetrahedron Journal for Research at the Interface of Chemistry and Biology
- Publishes international mix of highly cited papers on both chemical biology and medicinal chemistry
- Rapid Publication – from acceptance to online availability in under 1 week
- Increasing citations – ranked amongst the top ten most cited journals in Medicinal Chemistry*

Bioorganic & Medicinal Chemistry Letters
- The Tetrahedron Journal for Research at the Interface of Chemistry and Biology
- Publishes many cutting edge discoveries from leading pharmaceutical companies – including one of the first reported disclosures of Viagra™
- Rapid Publication – from acceptance to online availability in under 1 week
- Published #2 most requested article in 2005, as recognised by CAS Science Spotlight
- #2 highest cited journal in Medicinal Chemistry*

European Journal of Medicinal Chemistry
- The European publication for all aspects of Medicinal Chemistry
- Published under the auspices of the French Société de Chimie Thérapeutique (SCT)
- Publishing leading research in Medicinal Chemistry for over 35 years
- Online article submission – authors benefit from even faster publication times

www.elsevier.com/chemistry
YOUNG RESEARCH FELLOWS MEETING

January 31, 2008
Paris, France
www.sct.asso.fr

Organising committee:
X. Cachet, E. Braud, I. Berquet-Bestel,
F.-H. Porée, S. Routier
Contact person: Xavier Cachet
Tel: +33 1 5373 9805
xavier.cachet@univ-paris5.fr

Organised by:
Société de Chimie Thérapeutique (France)

1ST INTERNATIONAL CONFERENCE ON DRUG DESIGN AND DISCOVERY

February 3-6, 2008
Dubai, UAE
www.icddd.com/

Contact: Prof. Taleb Altel
Tel: +971 50 1732950 - Fax: +971 6 5585812
taltal@sharjah.ac.ae

FRONTIERS IN MEDICINAL CHEMISTRY

March 2-5, 2008
Regensburg, Germany
www.gdch.de/medchem2008

Organising committee:
Buschauer, Clement, Elz, Klebe, Ottow,
Schnorrenberg, Seifert, Stilz
Contact person: Prof. Dr. Armin Buschauer
Tel: +49 941 943 4827 - Fax: +49 941 943 4820
armin.buschauer@chemie.uni-regensburg.de

Organised by:
Division of Medicinal Chemistry of the German Chemical Society (GDCh) (Germany)
German Pharmaceutical Society, Section of Pharmaceutical/Medicinal chemistry (Germany)

THE CHALLENGES OF MULTI-TARGET DRUG DISCOVERY

March 10, 2008
The Institute of Physics
London, UK
www.confsec.co.uk

Organising committee: BMCS
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.uk

Organised by:
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)
JOINT MEETING
SCT-SFC-ACADÉMIE DE PHARMACIE
March 11, 2008
ENSCP
Paris, France
www.sct.asso.fr
Organising committee: SCT board
Contact person: Hervé Galons
Tel: +33 1 5373 9684
herve.galons@univ-paris5.fr
Organised by:
Société de Chimie Thérapeutique (France)

13TH PANHELLENIC SYMPOSIUM ON MEDICINAL CHEMISTRY
March 14-15, 2008
Athens, Greece
www.helmedchem2008.gr
Organising committee:
Mikros E. (University of Athens), Koufaki M. (IOPC/NHFR)
Contact person: A. Tsantili-Kakoulidou
Tel: +30 210 7274530 - Fax: +30 210 7274747
tsantili@pharm.uoa.gr
Organised by:
Hellenic Society of Medicinal Chemistry (HSMC) and Division of Organic and Medicinal Chemistry/Association of Greek Chemists (DOMC/AGC) (Greece)

19TH SYMPOSIUM ON MEDICINAL CHEMISTRY IN EASTERN ENGLAND
April, 2008
Hatfield, UK
www.confsec.co.uk
Organising committee: BMCS
Contact person: Dr. A. Faller
Tel: +44 1276 483036 - Fax: +44 1276 483525
faller_andrew@lilly.com
Organised by:
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)

DRUGS FROM NATURAL PRODUCTS IV
April 7-8, 2008
Cambridge, UK
www.confsec.co.uk
Organising committee:
BMCS & RSC Organic Division
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.uk
Organised by:
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) and RSC Organic Division(United Kingdom)

PROTEINASE 2008: FROM MOLECULES TO MEDICINES
April 21-22, 2008
SCI
London, UK
www.soci.org
Organising committee:
BMCS & Society for Chemical Industry
Contact person: Ms Jacqui Maguire
Tel: +44 20 7598 1562 - Fax: +44 20 7235 7743
jacqui.maguire@soci.org
Organised by:
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) and the Society for Chemical Industry(United Kingdom)

MINISYMPOSIUM ON “DRUG TARGETING”
May 29, 2008
Department of Chemistry, University of Basel,
St. Johannis-Ring 19
Basel, Switzerland
Contact person: Dr. Hans Peter Maerk
Tel: +41 61 688 5055 - Fax: +41 61 688 6459
hans_p.maerk@roche.com
Organised by:
Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS) (Switzerland)
<table>
<thead>
<tr>
<th>Event Title</th>
<th>Date</th>
<th>Location</th>
<th>Organising Committee</th>
<th>Contact Person</th>
<th>Tel/Fax/Email</th>
<th>Organised by</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHARMACOKINETICS AND DRUG METABOLISM FOR CHEMISTS</td>
<td>June 11, 2008</td>
<td>Liverpool, UK</td>
<td>Organising committee: BMCS</td>
<td>Ms Elaine Wellingham</td>
<td>+44 1275 853311 - Fax: +44 1275 853311 <a href="mailto:esw@confsec.co.uk">esw@confsec.co.uk</a></td>
<td>The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)</td>
</tr>
<tr>
<td>RICT 44 - RENCONTRES INTERNATIONALES DE CHIMIE THÉRAPEUTIQUE</td>
<td>July 2-4, 2008</td>
<td>Angers, France</td>
<td>Organising committee: Prof. Olivier Duval</td>
<td>Prof. Olivier Duval</td>
<td>+33 2 4122 6674 - Fax: +33 2 4122 6634 <a href="mailto:olivier.duval@univ-angers.fr">olivier.duval@univ-angers.fr</a></td>
<td>Société de Chimie Thérapeutique (France)</td>
</tr>
<tr>
<td>28TH EDITION OF THE EUROPEAN SCHOOL OF MEDICINAL CHEMISTRY (ESMEC)</td>
<td>July 6-11, 2008</td>
<td>Urbino, Italy</td>
<td>Organising committee: Bedini Lucia, Diamantini Giuseppe, Salvatori Americo, Spadoni Gilberto</td>
<td>Dr. Bedini Lucia</td>
<td>+39 0722 3033 23 - Fax: +39 0722 3033 13 <a href="mailto:chimfarm@uniurb.it">chimfarm@uniurb.it</a></td>
<td>Division of Medicinal Chemistry of the Italian Chemical Society (Società Chimica Italiana) (Italy)</td>
</tr>
<tr>
<td>INTERNATIONAL SYMPOSIUM ON THE INDUSTRIAL APPLICATIONS OF THE MOSSBAUER EFFECT</td>
<td>August 17-22, 2008</td>
<td>Budapest, Hungary</td>
<td>Organising committee: Ernő Kuzmann and Károly Lázár</td>
<td>Ernő Kuzmann</td>
<td>+36 1 209 0555, ext. 1152 - Fax: +36 1 372 2592 <a href="mailto:isiamec08@chem.elte.hu">isiamec08@chem.elte.hu</a></td>
<td>Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS) (Hungary)</td>
</tr>
<tr>
<td>SEVENTH INTERNATIONAL CONFERENCE ON NUCLEAR AND RADIOCHEMISTRY</td>
<td>August 24-29, 2008</td>
<td>Budapest, Hungary</td>
<td>Organising committee: Atilia Vértés and László Wojnárovits</td>
<td>Beatrix Body</td>
<td>+36 1 201 6883 - Fax: +36 1 201 8056 <a href="mailto:nrc7@mke.org.hu">nrc7@mke.org.hu</a></td>
<td>Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS) (Hungary)</td>
</tr>
<tr>
<td>METABOLIC DISORDERS - FROM BENCH TO BEDSIDE</td>
<td>August 28-31, 2008</td>
<td>Sopron, Hungary</td>
<td>Organising committee: Péter Mátys (Chairman), György Jermendy (Co-chairman)</td>
<td>Eszter Konrád</td>
<td>+36 1 201 6883 - Fax: +36 1 201 8056 <a href="mailto:mail@metdis2008.mke.org.hu">mail@metdis2008.mke.org.hu</a></td>
<td>Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS) and the Hungarian Diabetes Association (Hungary)</td>
</tr>
</tbody>
</table>
XXth INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY
AUGUST 31 - SEPTEMBER 4, 2008
Vienna, Austria
www.ismc2008.org

Contact person:
Dr. Peter Ettmayer
(Boehringer Ingelheim Austria GmbH)
info@ISMC2008.org

Organised by:
Austrian Chemical Society, Medicinal Chemistry Section (Austria) on behalf of the European Federation for Medicinal Chemistry (EFMC)

INTERNATIONAL CONFERENCE ON METROLOGY OF ENVIRONMENTAL, FOOD AND NUTRITIONAL MEASUREMENTS
SEPTEMBER 9-12, 2008
Budapest, Hungary
www.mefnm2008-budapest.org

Organising committee:
György Horvai (Chair), Péter Princz (Scientific Secretary)
Contact person: Beáta Androsits
Tel: +36 1 201 6883 - Fax: +36 1 201 8056
mefnm2008@mke.org.hu

Organised by:
Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS) (Hungary)

XIXth NATIONAL MEETING ON MEDICINAL CHEMISTRY
SEPTEMBER 14-18, 2008
GlaxoSmithKline Auditorium
Verona, Italy
www.nmmcverona2008.unimore.it

Organising committee:
Chairmen: Donati Daniele, Brasili Livio
Contact person: Prof. Mosti Luisa
Tel: +39 010 353 8350 - Fax: +39 010 353 8358
mosti@unige.it

Organised by:
Division of Medicinal Chemistry of the Italian Chemical Society (Società Chimica Italiana) (Italy)

GPCRs IN MEDICINAL CHEMISTRY II
SEPTEMBER 8-12, 2008
Gothenburg, Sweden
www.confsec.co.uk

Organising committee:
BMCS & Society for Chemical Industry
Contact person: Ms Elaine Wellingham
Tel: +44 1275 853311 - Fax: +44 1275 853311
esw@confsec.co.uk

Organised by:
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) and the Society for Chemical Industry (United Kingdom)

FALL MEETING OF THE SWISS CHEMICAL SOCIETY
SEPTEMBER 11, 2008
University of Zürich, Irchel Campus
Zürich, Switzerland

Organised by:
Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS) (Switzerland)

INTERFACES ‘08
SEPTEMBER 24-26, 2008
Sopron, Hungary
www.interfaces08.hu

Organising committee:
Árpád Olvasó (Chairman), András Kovács (Scientific Secretary)
Contact person: Beáta Androsits
Tel: +36 1 201 6883 - Fax: +36 1 201 8056
mail@interfaces08.hu

Organised by:
Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS) (Hungary)
**VIII JORNADAS DE LA SEQT**

**October 2008**

Carmona - Sevilla, Spain  
www.seqt.org

Contact person:  
Dr. Felipe Alcudia  
Tel: +34 954 55673 5 - Fax: +34 954 55673 7  
falcudia@us.es

Organised by:  
Sociedad Española de Química Terapéutica (Spain)

---

**ANNUAL ONE DAY MEETING ON MEDICINAL CHEMISTRY**

**October 2008**

Contact:  
SRC-KVCC Symposium  
Tel: +32 10 45 47 77  
Fax: +32 10 45 97 19  
secretariat@medchem.be

Organised by:  
Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCC) (Belgium) and Société Royale de Chimie (SRC), Medicinal Chemistry Division (Belgium)

---

**8TH SWISS COURSE ON MEDICINAL CHEMISTRY**

**October 12-17, 2008**

Leysin, Switzerland

Contact person: Prof. Beat Ernst  
Tel: +41 61 267 15 51 - Fax: +41 61 267 15 52  
beat.ernst@unibas.ch

Organised by:  
Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS) (Switzerland)

---

**2ND COAST TO COAST MEETING**

**October 26-29, 2008**

Poole, UK  
www.confsec.co.uk

Organising committee:  
BMCS & Society for Chemical Industry  
Contact person: Ms Elaine Wellingham  
Tel: +44 1275 853311 - Fax: +44 1275 853311  
esw@confsec.co.uk

Organised by:  
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) and the Society for Chemical Industry (United Kingdom)

---

**17TH LACDR SCHOOL ON MEDICINAL CHEMISTRY**

**Noordwijkerhout, the Netherlands**

**October 28-31, 2008**

Contact person:  
Erik de Vries  
Tel: +31-71-5274341, Fax: +31-71-5274277  
edevries@lacdr.leidenuniv.nl

Organised by:  
Leiden/Amsterdam Center for Drug Research

---

**SCT ANNUAL WORKSHOP IN MEDICINAL CHEMISTRY**

**December 2008**

Paris, France  
www.sct.asso.fr

Organising committee: Dr. Yves Rolland  
Contact person: Dr. Y. Rolland  
yves.rolland@fr.netgrs.com

Organised by:  
Société de Chimie Thérapeutique (France)
XXIst International Symposium on Medicinal Chemistry

August 2010
Brussels, Belgium
www.ismcs2010.org
Contact person:
Prof. Koen Augustyn (Universiteit Antwerpen)
Dr Edmond Differding (UCB S.A.)
info@ismcs2010.org
Organised by:
Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV) (Belgium)
Société Royale de Chimie (SRC), Medicinal Chemistry Division (Belgium) on behalf of the European Federation for Medicinal Chemistry (EFMC)

28th Noordwijk-Camerino-Cyprus Symposium on Trends in Drug Research
Noordwijk, The Netherlands
May 2009
Contact person:
Henk Timmerman
henk.timmerman@planet.nl

4th Anglo-Swedish Medicinal Chemistry Symposium
March 2009
Åre, Sweden
www.lakemedelsakademin.se
Contact person:
Ms Diana Mickels
Tel: +46 8 723 5085 - Fax: +46 8 2055 11
diana.mickels@lakemedelsakademin.se
Organised by:
Swedish Academy of Pharmaceutical Sciences (Sweden), The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)

Alzheimer Disease Medicinal Chemistry Symposium (part of KNCV Spring Symposium)
Congrescentrum De Reehorst, Ede, The Netherlands
17 April 2008
Contact person:
Hein Coolen
Tel: +31-294-479183, Fax: +31-295-477138
hein.coolen@solvay.com
Organised by:
Medicinal Chemistry Section of the Royal Netherlands Chemistry Society (KNCV)
Few, if any, products undergo more safety testing and scrutiny than a pharmaceutical. This, of course, is essential as the most critical issue with regard to pharmaceuticals is the risk benefit ratio. Whilst patient benefits can be quite clear in most cases, the risk of undergoing a treatment regimen must be as carefully and broadly quantified as possible. Often this characterisation results in findings that result in discontinuation or withdrawal. Thus as drug withdrawals and experimental therapeutics that do not fulfil safety criteria during preclinical and clinical trials are regarded as ‘failures’, they are actually successes for patient safety and for the science base of drug discovery. The lessons learned and the data gathered during this sometimes painful process is of critical importance in buttressing future efforts against similar problems.

The failure of a drug or clinical candidate is invariably associated with a massive amount of basic science that goes into problem-solving activities. This effort, if captured and integrated into the Discovery process, can contribute to the development of better and more sophisticated approaches to discovery safety assessment and meaningful refinements in the regulation of drug development and approval. Thus, the resources and momentum behind a problem solving effort, particularly around a late-stage clinical candidate present a unique opportunity to develop a more stable and valid science base upon which to build a more rational approach to discovery safety.

What does an increase in the sophistication of a safety science base look like and to whom should it be directed? The choice of therapeutic target is one critical area and many advances have been made in recent years in the characterisation of a protein’s role in various tissues. This ‘target safety’ aspect is not a one-time exercise to be carried out at the beginning of a project, but, as the recent experience with Vioxx has shown us, a constant vigil to relate all aspects of the complicated life of a therapeutic target to the adverse event signals coming from our preclinical and clinical studies.

The Role of the Medicinal Chemist in Safety

It is the area of chemical design that perhaps the most value can be gained from translating safety data to real, tangible decisions. This is a long, tedious process but several successful examples have been identified in which a valid set of decision-making tools can be used to warn for chemical designs that contain inherent safety liabilities. In some cases this can lead to decisions before synthesis is even undertaken. In other cases the level of confidence is lower, but the tool can spark the decision to do further experiments in more sophisticated model systems to investigate the probability of a real safety problem. The key to either of these scenarios is first, a clear strategy behind the decision-making tools such that results from a simple test (SAR, QSAR, in vitro) can be followed up and confirmed in a relevant in vivo test and second, adequate throughput to facilitate iterative design. Without this confirmation mechanism very little about the real risk of a compound or series can be concluded and without adequate throughput the medicinal chemist will be mired in indecision.

What kinds of safety-related decisions can be made by the medicinal chemist? There are actually many. First and foremost one should always be cognisant of the area of chemistry in which one is working, the therapeutic class of compounds, and any similarities they may
have, both in their basic structure and in their pharmacophoric makeup, to compounds with known pharmacologies. Polypharmacology, whilst desirable in some special cases (1) carries the potential to add an unnecessary burden to the drug development project and in many cases, can be identified and avoided by early searching of pharmacology datasets like PubChem (2), GVKBio (3) or BioPrint (4) or by performing broad ‘secondary pharmacology’ screening at highly skilled and efficient contract organisations like Cerp (5) or MDS Pharma (6). This sort of characterisation hardly ever leads to the decision to stop a chemical series, but rather aids in the identification of potential problems early enough to guide confirmatory experimentation (monitoring of blood pressure in early preclinical species for compounds active at the alpha1 adrenergic receptor, for example) and allows chemistry to be changed such that liabilities can be designed out if they are judged to be serious enough.

A specific case of unwanted pharmacology, of course, is activity at the cardiac hERG K+ channel. Potent blockers of the hERG channel can be found in most therapeutic classes and thus few industrial medicinal chemists have escaped this problem entirely. Fortunately, there have been many advances in our understanding of hERG specificity and the physicochemical properties that drive hERG blockade. Homology models of the channel are now available and scores of papers have been published on hERG structure-activity-relationships (7). Whilst building away from hERG blockade while retaining all other properties remains a huge challenge, the combination of better foundation tools such as SAR and protein models, combined with enhanced screening technologies (8) and a constantly improving picture of the preclinical and clinical testing systems required to assess the ultimate risk of fatal arrhythmias (9) has dramatically improved our ability to successfully manage this once-difficult problem. As mentioned above, high resolution preclinical and clinical studies on causal mechanisms of safety problems allow for identification of the chemical events underlying these mechanisms.

Blockade of hERG is one of these cases and now medicinal chemists, armed with the right tools, can in most cases successfully build out hERG liabilities. A list of the full compliment of hERG-related tests is given in (10).

A few simple rules for avoiding hERG activity

Avoid extended cylinder-shaped molecules with hydrophobic cores at the ends

* Avoid amines with a pKa above 7

* Avoid compounds with logP or logD values over 2

In most cases, potent activity at the hERG channel is a ‘show stopper’ for the project and it must be addressed. Another such endpoint is genetic toxicity. As with hERG (11), genetic toxicity (12) testing is part of a mandated set of tests that must be performed before humans are exposed to a new drug candidate. As such it must be effectively dealt with in the early phase of a project to avoid a significant issue later in the more mature project. Several very effective tools are available for the medicinal chemist that range from structural warnings (13,14,15) to SAR and QSAR models with reasonable levels of predictivity (16,17,18,19). Screens for genetic alterations also come in a number of types with the most common for drug development being the Salmonella reverse mutation, or ‘Ames’ test and the Mouse Lymphoma assay. Several other genetic toxicity test exist and they are listed in (20) along with their intended use and, most importantly, a current view on their ability to actually predict carcinogens.

A few simple rules for avoiding Ames activity

Avoid reactive species

* Avoid aromatic amines or compounds that give aromatic amine metabolites

* Avoid compounds that can produce other forms of reactive metabolites
As the last point above illustrates, reactive metabolites are a problem for drug development. Reactive metabolites (21) can either be relatively ‘silent’, e.g., though present in significant amounts and not cause overt problems in preclinical and early clinical studies, or they can be more direct and thereby be clearly associated with organ-based toxicities. Silent reactive intermediates like those associated with halothane have the potential to bloom into quite serious problems in the clinic as more and more patients are exposed and may become apparent only after years of use in patients. These reactions are sometimes labelled ‘idiosyncratic’ although in reality the seeds of a serious safety problem were already sown by the medicinal chemist. Direct, organ-based toxicity by compounds producing reactive intermediates, such as paracetamol, is also possible and is usually easier to detect early because they cause a more dose-related lesion that is seen across species and in nearly all individuals exposed. What about those compounds that produce reactive intermediates but have not been shown to produce either direct or idiosyncratic toxicities? Do these represent a set of compounds or lesions that are benign or are they examples of the safety issues of the future when enough patient experience have accumulated and/or enough overdoses have occurred? It is important for medicinal chemists to appreciate that we do not know!

Thus prudence, both to avoid unnecessarily burdening the project and to act responsibly towards our future patients would dictate that we identify those functional groups that can give rise to reactive metabolites and at the very least be aware of them and preferably avoid them. Awareness can also aid the interpretation of safety studies when unexpected pathologies are observed. A catalogue of in vivo pathologies that have been associated with reactive intermediates is a very useful tool to be used in combination with a thorough library of the functional groups and substructures that can give rise to reactive intermediates.

A few simple rules for avoiding reactive intermediates

- Actively use a ‘warning’ substructure list
- Characterise biotransformation as early as possible
- Look for warning signs: toxicity in genetic tox assays using metabolic activation, time-dependent inhibition of P450 activity, cytotoxicity in P450-expressing cell lines (22)
- Assess degree of binding in combination with the intended dose. The higher the dose, the greater the reactive metabolite burden

What advice can be given to the medicinal chemist wishing to assess structures for liabilities outside these few areas? Online structure toxicity resources such as ChemIDPlus (23), IUCLID (24), TOXNET (25) and DSSTox (26) can compliment the commercial information/model tools such as MultiCASE (27) and DEREK (28). A recent, potentially useful addition to this group is the Mechanism Based Toxicity database from GVKBio (29), a hand-annotated, structure-searchable database of reported toxicities. The current version of this database contains over 13000 entries.

In vitro tests are too numerous to list here, but several new and useful test have recently been reviewed (30). The general trend is to move away from gross cytotoxicity assays in the target cell/tissue type and to instead focus on either non-lethality measures in target cell types or measurements of general interference in basic cellular processes via the monitoring of several endpoints simultaneously (31). Additionally, recent examples of promising applications of toxicogenomics give hope that this technique will finally begin to live up to the initial promise (32,33). There is an almost universal desire to enhance the predictivity of early toxicology screens and this has lead to a number of products and initiatives to improve
the general area of ‘Predictive Toxicology’. But do we have the patience to validate these methods?

**Predictive Toxicology: The twilight zone**

There are several promising technologies that are commonly lumped under the heading of ‘predictive toxicology’ and are, naturally, under varying stages of development and validation. Often one is exposed to these approaches and technologies too early in their development and a generally negative and sceptical attitude develops toward all predictive toxicology approaches. This is unfortunate as many of these are indeed sound basic ideas that suffer from inadequate validation and testing and/or are used for applications outside their originally intended purpose. Thus one can lament the failure rate of drugs and drug candidates, but the failure rate of predictive technologies is, in practice, probably many times higher. That said, why engage these at all? Because some of them actually appear to yield useful information, particularly if enough data are accumulated within a single chemical series to make series-specific structure-toxicity-relationships. The same risk-benefit argument that is used to justify embarking on a drug treatment can be used when committing to the exploitation of a ‘predictive toxicology’ technology. It may not work for everyone in all cases, but the risk of failure is worth the benefit of enlightened chemical design and the potential of project progression and/or competitive advantage. Also, the effectiveness of a new method is only truly tested with an adequate (large) number of examples; examples that may take years to accumulate. Few organisations possess this level of patience and thus the demise of potentially useful predictive toxicology approaches is usually swift and unfortunately premature.

**Will it help?**

Those who choose only the tried and proven methods of discovery safety assessment are in danger of missing true opportunities in the technologies of the predictive toxicology twilight zone. Conversely, those who do not fully exploit the ‘fundamental’ methods as a foundation upon which to base a diversity of approaches may not only be doing themselves and their organisations a disservice, but they are also neglecting the fact that toxicology data, whether it be from animals or from humans, has been produced through studies designed to explore the edges of tolerability of a drug and thus a certain degree of adversity accompanied producing the data in the first place. With that consideration, as a species with a capacity for ethical behaviour, we owe it to ourselves and our fellow species to use as much toxicology data as possible to inform and improve as many aspects of our early drug discovery decisions as possible.

With the goal of integrating as much of this rapidly expanding sophistication into chemical design, the potential for reducing safety-related failures exists, but is far from certain. One certain effect will be that promising compounds will fail less often for the reasons of yesterday. Rather, the problems of the future will be qualitatively different, but if we have done a conscientious job in addressing the problems of yesterday, we will free up more time and resources within our safety groups for problem-solving around more of tomorrow’s problems. That, despite the real potential for continued failure, is progress and thus a success in itself.
References

11. ICH Topic S7A: Safety pharmacology studies for human pharmaceuticals CPMP/ICH/539/00; ICH Topic S7B: The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals CPMP/ICH/423/02; ICH Topic E14: the Clinical Evaluation of QT/QcI Interval Prolongation and Proarrhythmic Potential for Non-Antiarrrhythmic Drugs CHMP/ICH/2/04
27. http://www.multicase.com
Top Quality Bioscience Journals

*Molecular BioSystems* is a high quality chemical biology journal with a focus on the interface between chemistry and the -omic sciences and systems biology.
Impact factor: 2.45*

www.molecularbiosystems.org

*Organic & Biomolecular Chemistry* is an international journal for the quickest publication of high-quality research covering the breadth of synthetic, physical and biomolecular chemistry
Impact factor: 2.874*

www.rsc.org/obc

*National Product Reports (NPR)* is a critical review journal which stimulates progress in all areas of natural products research.
Impact factor: 8.89*

www.rsc.org/npr

*Photochemical & Photobiological Sciences* is a photoscience journal with rapid publication times and the highest impact factor in its field.
Impact factor: 2.416*

www.rsc.org/pps

Submit your work today!

*2006 Thompson Scientific (ISI) Journal Citation Reports*
RSC Biomolecular Sciences Series

The RSC Biomolecular Sciences Series is devoted to the coverage of the interface between the chemical and biological sciences, especially structural biology, chemical biology, bio- and chemo-informatics, drug discovery and development, chemical enzymology and biophysical chemistry. The books are ideal as a reference and state-of-the-art guides at the graduate and postgraduate levels.

Structure-Based Drug Discovery An Overview
Edited by R E Hubbard

"There are very few of us who will invent a drug, but by using the techniques described (in this book), you will shorten your own odds considerably."
Reviewed in Chemistry World
2006 | xvi+262 pages | 978 0 85404 351 4 | £74.95

Exploiting Chemical Diversity for Drug Discovery
Edited by P A Bartlett and M Entzeroth

"Is an excellent and astonishingly complete compilation on this broad and demanding topic for current practitioners."
Reviewed in Angewandte Chemie
2006 | xxiv+420 pages | 978 0 85404 842 7 | £119.95

Sequence-specific DNA Binding Agents
Edited by M Waring

"An excellent overview of the work being done in the exciting areas of discovering agents that exhibit selectivity and sequence specificity for DNA."
Reviewed in ChemBioChem
2006 | xii+258 pages | 978 0 85404 370 5 | £79.95

Forthcoming Winter 2007

Metabolomics, Metabonomics and Metabolite Profiling
Edited by: W Griffiths
ISBN: 978085404299
Price: £89.00

Ribozymes and RNA Catalysis
Edited by: D M J Lilley and F Eckstein
ISBN: 9780854042531
Price: £79.95

Computational and Structural Approaches to Drug Discovery
Edited by: R Stroud and J Finer-Moore
ISBN: 9780854043651
Price: £89.00

RSCPublishing

www.rsc.org/books
Registered Charity Number: 207890
<table>
<thead>
<tr>
<th>Country</th>
<th>Adhering Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>Austrian Chemical Society, Medicinal Chemistry Section</td>
</tr>
<tr>
<td>Belgium</td>
<td>Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV) Société Royale de Chimie (SRC), Medicinal Chemistry Division</td>
</tr>
<tr>
<td>Denmark</td>
<td>The Danish Society for Pharmacology and Toxicology</td>
</tr>
<tr>
<td>France</td>
<td>Société de Chimie Thérapeutique</td>
</tr>
<tr>
<td>Germany</td>
<td>Division of Medicinal Chemistry of the German Chemical Society (GDCh) German Pharmaceutical Society, Section of Pharmaceutical/Medicinal chemistry</td>
</tr>
<tr>
<td>Greece</td>
<td>Hellenic Society of Medicinal Chemistry</td>
</tr>
<tr>
<td>Hungary</td>
<td>Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS)</td>
</tr>
<tr>
<td>Israel</td>
<td>The Medicinal Chemistry Section of the Israel Chemical Society</td>
</tr>
<tr>
<td>Italy</td>
<td>Division of Medicinal Chemistry of the Italian Chemical Society (Società Chimica Italiana)</td>
</tr>
<tr>
<td>Latvia</td>
<td>Latvian Association for Medicinal Chemistry</td>
</tr>
<tr>
<td>Poland</td>
<td>Polish Society of Medicinal Chemistry</td>
</tr>
<tr>
<td>Portugal</td>
<td>Group of Medicinal Chemistry of the Portuguese Chemical Society</td>
</tr>
<tr>
<td>Russia</td>
<td>The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section</td>
</tr>
<tr>
<td>Slovenia</td>
<td>Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society</td>
</tr>
<tr>
<td>Spain</td>
<td>Sociedad Española de Química Terapéutica</td>
</tr>
<tr>
<td>Sweden</td>
<td>The Swedish Academy of Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS)</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>Section of Pharmacochemistry, Royal Netherlands Chemical Society (KNCV)</td>
</tr>
<tr>
<td>Turkey</td>
<td>Turkish Association of Medicinal and Pharmaceutical Chemistry</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) Society for Medicines Research</td>
</tr>
</tbody>
</table>
AUSTRIAN CHEMICAL SOCIETY, Medicinal Chemistry Section

To foster medicinal chemistry in Austria by jointly organising and hosting national and international summerschools, minisymposia and workshops together with the Austrian Pharmaceutical Society.

1999
100

Trade and Industry: 27%
Research Institute and University: 46%
Others: 27%

Nibelungengasse 11/6
AT-1010 Vienna Austria

+43 1 587 42 49 or +43 1 587 39 80
+43 1 587 89 66

office@goech.at
www.goech.at

XXth International Symposium on Medicinal Chemistry • (August 31 - September 4, 2008), Vienna, Austria

Prof. Marko MIHOVILOVIC
(TU VIENNA)

Mrs Gabriela EBNER
(AUSTRIAN CHEMICAL SOCIETY)

Dr. Peter ETTMAYER
(BOEHRINGER INGELHEIM AUSTRIA GmbH)
**Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV)**

<table>
<thead>
<tr>
<th>Mission</th>
<th>Organisation of symposia and activities. Promotion of contacts between industry and academia Promotion of contacts with other national and international organisations.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Founded</td>
<td>2002</td>
</tr>
<tr>
<td>Members</td>
<td>120</td>
</tr>
</tbody>
</table>
| Postal address | Celestijnenlaan 200F  
BE-3001 Herverlee Belgium                                                                                                                                 |
| Telephone | +32 16 29 32 14  
+32 16 22 68 92                                                                                                                                 |
| Fax      | info@kvcv.be  
www.kvcv.be                                                                                                                                 |
| E-mail Website |                                                                                                                                 |
| Activities | Every 2 years the J&J PRD award for Medicinal Chemistry is given to an outstanding Ph.D. thesis in the field  
- Annual One Day Meeting on Medicinal Chemistry (October 2008)  
- XXIst International Symposium on Medicinal Chemistry (August 2010), Brussels, Belgium |
| President | Prof. Koen AUGUSTYNS  
(UNIVERSITEIT ANTWERPEN) |
| Secretary | Dr. Peter TEN HOLTE  
(J&J PRD) |
| EFMC-Delegate | Prof. Koen AUGUSTYNS  
(UNIVERSITEIT ANTWERPEN) |
Passion for progress, care for people

We want to apply genuine innovation in carefully chosen areas in order to meet as yet unfulfilled medical needs. Pioneering research is needed for this. We conduct this research with great passion, commitment and resolve.

After all, we are talking about the health of human beings. This demonstrates the responsibility of Solvay Pharmaceuticals as an international pharmaceutical company for the world in which we live.
**Société Royale de Chimie (SRC),**
**Medicinal Chemistry Division**

**Mission**
The Division of Medicinal Chemistry of the SRC provides a forum for scientists interested in medicinal chemistry and related areas in pharmaceutical research. The Division’s activities intend to bring together its members and to foster contacts in a European context.

**Founded**
1973

**Members**
120

**Postal address**
ULB, CP 160/07
Avenue F. Roosevelt, 50
BE-1050 Bruxelles Belgium

**Telephone**
+32 2 650 52 08
+32 2 650 51 84

**Fax**
src@ulb.ac.be
www.src.be

**Website**

**Activities**
The DMC confers, every 2 years, the «Johnson and Johnson Pharmaceutical Research and Development Award for Young Medicinal Chemists» to acknowledge an outstanding Ph.D. thesis work.

The DMC organises annually a Symposium aimed at updating interested participants on particularly rapidly evolving areas of pharmaceutical research, by specialists in their respective field.

- Annual One Day Meeting on Medicinal Chemistry (October 2008).

- XXIst International Symposium on Medicinal Chemistry (August 2010), Brussels, Belgium

**President**
Dr. Edmond DIFFERDING
(UCB)

**EFMC-Delegate**
Dr. Edmond DIFFERDING
(UCB)
To advance the development of pharmacology, toxicology and medicinal chemistry.

377 members of which 120 are members of the medicinal chemistry section.

Trade and Industry: 50%
Research Institute and University: 50%

Att. Inger Marie Bro
Wilh. Meyers Alle, bygning 240
Bartholinbygningen, Univ.park
DK - 8000 Århus C Denmark

+45 89 42 17 26
+45 86 12 88 04

imb@farm.au.dk
www.dsft.dk

5-10 yearly seminars on current topics in pharmacology, toxicology and medicinal chemistry.

Danish Pharmacology 2008 • (January 16, 2008), Odense, Denmark
Annual Meeting - « Early Drug Discovery » • (May 15-16, 2008), Copenhagen, Denmark

Prof. Ulf SIMONENSEN
(UNIVERSITY OF AARHUS)
Assoc. Prof. Mette M. ROSENKILDE
(UNIVERSITY OF COPENHAGEN)
Prof. Kristian STRØMGAARD
(UNIVERSITY OF COPENHAGEN)
Société de Chimie Thérapeutique

**Mission**
To gather medicinal chemists in order to promote progress in Medicinal Chemistry by organising meetings, distributing awards and grants, encouraging junior scientists and publishing medicinal chemistry journals or series.

**Founded**
1966

**Members**
302

**Member profile**

- Trade and Industry: 17%
- Research Institute: 8%
- University: 70%
- Other: 5%

**Postal address**
5, rue Jean-Baptiste Clément
FR-92296 Chatenay-Malabry France

**Telephone**
+33 1 46 83 56 84
+33 1 46 83 53 23

**Fax**

**E-mail**
herve.galons@univ-paris5.fr

**Website**
www.sct.asso.fr

**Activities**
Organisation of meetings and conferences.

**Awards:**
Every two-year: *Prix Charles Mentzer*, rewarding a fruitful career in Medicinal Chemistry. Every year: *Prix d’encouragement à la recherche en Chimie Thérapeutique*, for junior scientists. *Paul Ehrlich Lecture*, attributed during the annual meeting. *Prix de la vocation en Chimie Thérapeutique*, attributed to students during the annual meeting.

**Publishing activities:**
Actualités de Chimie Thérapeutique, 1 volume per year (2004 n° 30).

- Young Research Fellows Meeting
  (January 31, 2008), Paris, France
- Joint Meeting SCT - SFC - Académie de Pharmacie
  (March 11, 2008), Paris, France
- RICT 44 - Rencontres Internationales de Chimie Thérapeutique.
  International Conference in Medicinal Chemistry: Interfacing Chemical Biology, Natural Products and Drug Discovery
  (July 2-4, 2008), Angers, France
- SCT Annual Workshop in Medicinal Chemistry
  (December 2008), Paris, France

**President**
Dr. Yves ROLLAND (SERVIER)

**Secretary**
Prof. Hervé GALONS (UNIVERSITÉ PARIS V)

**EFMC-Delegate**
Prof. Olivier LAFONT (FACULTÉ DE MéDECINE ET DE PHARMACIE DE ROUEN)
With R&D spending of more than €1.4 billion a year, we’re always seeking talent and ideas. Maybe yours?

Boehringer Ingelheim equates success as a pharmaceutical company with developing therapies that make a difference. R&D is our driving force. Our scientific teams strictly focus on innovation, with a devotion to excellence. We collaborate with academic institutions and businesses around the world, transforming good ideas into outstanding products. All this creates a global community of innovators dedicated to improving human health.

www.boehringer-ingelheim.com
Division of Medicinal Chemistry
of the German Chemical Society (GDCh)

To foster the whole area of Medicinal Chemistry in University and Pharmaceutical Industry. The Division builds an interdisciplinary bridge between Chemistry, Biology, Medicine and Pharmacy.

1971 at Karlsruhe, Germany
650 Members

Trade and Industry: 60%
Research Institute and University: 35%
Other: 5%

Varrentrappstr. 40-42
DE-60486 Frankfurt am Main Germany
+49 69 7917 363
+49 69 7917 450

U.Bechler@gdch.de
www.gdch.de/medchem

Annual meetings, interdisciplinary symposia, scientific publications, award.

• Frontiers in Medicinal Chemistry (March 2-5, 2008), Regensburg, Germany

Dr. Hans-Ulrich STILZ
(AVENTIS PHARMA DEUTSCHLAND GmbH)
Prof. Dr. Gerd SCHNORRENBERG
(BOEHRINGER INGELHEIM PHARMA KG)
To foster the whole area of Medicinal Chemistry in University and Pharmaceutical Industry by annual meetings, awards and activities related to the education in Medicinal Chemistry.

1985
679

Trade and Industry: 20%
University: 60%
Others: 20%

Hamburger Allee 26-28
DE-60486 Frankfurt am Main Germany

+49 69 7917 555
+49 69 7917 553
info@dphg.de
www.dphg.de

Annual awards in Medicinal Chemistry (Germany), cooperations with other organisations, support of the education in Medicinal Chemistry, annual meetings.

Frontiers in Medicinal Chemistry • (March 2-5, 2008), Regensburg, Germany

Prof. Dr. Bernd CLEMENT
(UNIVERSITÄT KIEL)
### Hellenic Society of Medicinal Chemistry

**Mission**
Advancement of research in Medicinal Chemistry and Drug Design, promotion of cooperation between scientists of related fields and consulting on relevant subjects.

**Founded**
1980

**Members**
107

**Member profile**
Trade and Industry: 20%
Research Institute: 30%
University: 40%
Other: 10%

**Postal address**
School of Pharmacy, Department of Pharmaceutical Chemistry, University of Athens, Greece
Panepistimiopolis, Zografou
GR-157 71 Athens Greece

**Telephone**
+30 210 7274 530

**Fax**
+30 210 7274 747

**E-mail**
tsantili@pharm.uoa.gr, snikolar@upatras.gr

**Activities**
Symposia, seminars, consulting.

- 13th Panhellenic Symposium on Medicinal Chemistry (March 14-15, 2008), Athens, Greece

**President**
Assoc. Prof. Dr. Anna TSANTILI-KAKOULIDOU
(UNIVERSITY OF ATHENS)

**Secretary/Treasurer**
Assist Prof. Dr. Sotiris NIKOLAROPOULOS / Dr. Ioanna ANDREADOU
(UNIVERSITY OF PATRAS / UNIVERSITY OF ATHENS)

**EFMC-Delegate**
Assoc Prof. Anna TSANTILI-KAKOULIDOU
(UNIVERSITY OF ATHENS)
Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS)

The dissemination of results and particularly of new trends in organic and medicinal chemistry among Hungarian scientists.

**Mission**

1907 (HCS)

300 (Medicinal Chemistry oriented members of the OMCD)

**Founded**

**Members**

Trade and Industry: 40%
Research Institute: 20%
University: 30%
Others: 10%

**Member profile**

Fő u. 68
HU-1027 Budapest Hűngary

+36 1 201 6883
+36 1 201 8056
mail@mke.org.hu
www.mke.org.hu

**Postal address**

**Telephone**
Fax
E-mail
Website

**Activities**

Regular organisation of conferences, seminars and lectures in various fields of medicinal chemistry. Encouragement and initiating the development of new generations of scientists working in this field. Bimonthly seminars by invited scientists in the field of medicinal chemistry.

International Symposium on the Industrial Applications of the Mössbauer Effect (August 17-22, 2008), Budapest, Hungary
Seventh International Conference on Nuclear and Radiochemistry (August 24-29, 2008), Budapest, Hungary
Metabolic Disorders - from Bench to Bedside (August 28-31, 2008), Sopron, Hungary
International Conference on Metrology of Environmental Food and Nutritional Measurements (September 9-12, 2008), Budapest, Hungary
INTERFACES ‘08 (September 24-26, 2008), Sopron, Hungary

Prof. Dr. Péter MÁTYUS (SEMMLERWIS UNIVERSITY)
Dr. János WÖLFLING (UNIVERSITY OF SZEGERD)
Dr. János WÖLFLING (UNIVERSITY OF SZEGERD)

**President**

Secretary
EFMC-Delegate
To organise and to foster the interaction between medicinal chemists in academia, industry and drug dispensing institutions, in an independent Association devoted to education, research and development of Medicinal Chemistry through meetings and workshops, and to represent the Association at the national level, at the EFMC, and at related international levels. IAMC is open for membership to molecular biologists, pharmacologists and pharmacists.

1991

2004 united with the Israel Association for Medicinal Chemistry

200

Trade and Industry: 35%
Research Institute and University: 60%
Other: 5%

Department of Medicinal Chemistry and Natural Products
School of Pharmacy – Faculty of Medicine
Hebrew University of Jerusalem
PO Box 12065
IL-91120 Jerusalem, Israel

+972 2675 75 73, cell: +972 52 4282677
+972 2675 70 76
avid@ekmd.huji.ac.il
www.weizmann.ac.il/conferences/medchem/

The Association holds symposia and annual scientific meetings. Promotion of one-day symposia on new vistas in drug research and a workshop on progress in instrumental drug analysis, and representation of the Association at the EFMC and related international bodies.

Prof. Abraham DOMB J.
(HEBREW UNIVERSITY OF JERUSALEM)

Dr. Jeffrey STERLING
(TEVA PHARMACEUTICAL Ind.)
To improve Medicinal Chemistry in academia and industry by promoting contacts and collaboration between researchers working in this and related fields with the aim to propose and develop projects to advance Medicinal Chemistry; to organise national and international meetings, interdisciplinary symposia and advanced schools to spread the knowledge in drug development; to distribute awards and grants that encourage junior scientists to pursue research in Medicinal Chemistry; to cooperate with similar associations in the country and abroad.

1979
578

Trade and Industry: 13%
Research Institute: 0.5%
University: 86%
Other: 0.5%

Division di Chimica Farmaceutica
University of Genova-Dipartimento di Scienze Farmaceutiche
Viale Benedetto XV, 3
IT-16132 Genova Italy
+ 39 010 353 8350
+ 39 010 353 8358
mosti@unige.it
dcf.frm.uniroma1.it/cgi-bin/home.pl

28th Edition of the European School of Medicinal Chemistry (ESMEC) •
(July 6-11, 2008), Urbino, Italy
XIXth National Meeting on Medicinal Chemistry •
(September 14-18, 2008), Verona, Italy

Prof. Luisa MOSTI
(UNIVERSITY OF GENOVA)
Prof. Dr. Antonello MAI
(UNIVERSITY DI ROMA «LA SAPIENZA »)
Prof. Carlo FRANCHINI
(UNIVERSITY OF BARI)
Prof. Luisa MOSTI
(UNIVERSITY OF GENOVA)
# Latvian Association for Medicinal Chemistry

**Founded**: 1992  
**Members**: 12  

**Member profile**: Research Institute and University: 83%  
Other: 17%  

**Postal address**: Latvian University  
Institute of Microbiology and Biotechnology  
4-402 Kronvalda Boulevard  
LV-1586 Riga Latvia  

**Telephone**: +371 7034890  
+371 7323065  

**Fax**: vina@lanet.lv  

**E-mail**: vina@lanet.lv  

**Activities**: Promotion of medicinal chemistry  

**President**: Dr. Ilmara VINA  
(LATVIAN UNIVERSITY)  

**EFMC-Delegate**: Prof. Dr. Gunars DUBURS  
(LATVIAN INSTITUTE OF ORGANIC SYNTHESIS)
Group of Medicinal Chemistry of the Portuguese Chemical Society

Mission
- To diffuse the knowledge of Medicinal Chemistry.
- To foster interdisciplinary bridges between Chemistry, Biology, Medicine and Pharmacy.
- To encourage research among young students.
- To promote the interaction between medicinal chemists in academia and professionals in industry.

Founded
2007

Members
62

Postal address
Sociedade Portuguesa de Química
Av. da República, 37-40
PT-1050 187 Lisboa Portugal

Telephone
+351 21 793 4637
+351 21 795 2349

Fax
E-mail
sede@spq.pt

Website
www.spq.pt

Activities
Promotion of activities to reach a high experience and development in Medicinal Chemistry and to push every boundary to integrate education and research in the area.

Organisation of meetings, advanced courses and seminars in different areas of Medicinal Chemistry.

A National Meeting in Medicinal Chemistry is planned for December 2008.

President
Prof. M. Luisa SÁ E MELO
(UNIVERSITY OF COIMBRA)

EFMC-Delegate
Prof. Rui MOREIRA
(UNIVERSITY OF LISBON)
**The D.I. Mendeleev Russian Chemical Society**  
**Medicinal Chemistry Section**

Education in medicinal chemistry.  
Organisation of regular scientific seminars.

**Founded**
2000

**Members**
150

Research Institute: 67%
University: 26%
Other: 7%

RU-119899 Moscow Russia

+ 7 095 939 1620
+ 7 095 939 0290

zefirov@org.chem.msu.ru

Organising regular and specific seminars in medicinal chemistry.  
Assisting in the organisation of regular courses for undergraduate students of Moscow State University in medicinal chemistry.  
Providing interaction between Russian academician research in the field of medicinal chemistry and industrial institutions.

Prof. Dr. Nikolay S. ZEFIROV  
(MOSCOW STATE UNIVERSITY)

EFMC-Delegate
Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society

The mission of the Section for Medicinal Chemistry of the Slovenian society is the advancement and promotion of medicinal chemistry in Slovenia and Europe. It will pursue its mission by organising scientific meetings, schools and working-group in order to encourage discussions and exchange of ideas in the field of medicinal chemistry. This section will cooperate with similar associations in the country and abroad.

23 February 2004
28

Trade and Industry: 20 %
Research Institute: 15 %
University: 60 %
Others: 5 %

University of Ljubljana, Faculty of Pharmacy
Aškerceva 7
SI- 1000 Ljubljana Slovenia

+386 1 4769561
+386 1 4258031
danijel.kikelj@ffa.uni-lj.si
www.farmacevtsko-drustvo.si

Dr. Lucija PETERLIN MAŠIC
(UNIVERSITY OF LJUBLJANA)
Prof. Danijel KIKELJ
(UNIVERSITY OF LJUBLJANA)
Sociedad Española de Química Terapéutica

To assist in the development and improvement of research and training in the different areas of Medicinal Chemistry throughout Spain.

1977
375

Trade & Industry: 25%
Research Institute: 30%
University: 35%
Other: 10%

SEQT
Juan de la Cierva, 3
ES-28006 Madrid Spain

+34 91 56 22 900
+34 91 56 44 853
seqt@iqm.csic.es
www.seqt.org

Supporting the participation of young researchers at meetings and other educational events. Organising symposia on topics related with research and education towards the discovery of new drugs. Sponsoring the Spanish Society of Medicinal Chemistry Award. Administrating five Awards addressed to young scientists to acknowledge outstanding research in the field of Medicinal Chemistry.

VIII Jornadas de la SEQT •
(October 2008), Carmona - Sevilla, Spain

Dr. María L. López-Rodríguez
(UNIVERSIDAD COMPLUTENSE DE MADRID)
Dr. Ana Rosa San Félix García
(IQM-CSIC)
Dr. Sonsoles Velázquez Díaz
(IQM-CSIC)
Dr. Marina Gordaliza-Escobar
(UNIVERSIDAD DE SALAMANCA)
Empowering knowledge-based drug discovery and development

The preferred drug R&D portal where knowledge areas are coordinated to provide a harmonious, interrelated whole.

Knowledge Areas include:
Drugs & Biologics, Targets & Pathways, Genomics, Biomarkers, Organic Synthesis, Experimental Pharmacology, Pharmacokinetics and Metabolism, Clinical Studies, Disease Briefings, Companies & Research Institutions, Literature and Patents.

To learn how Integrity® and other Prous Science products can empower your drug R&D activities, point your browser to www.prous.com

http://integrity.prous.com
To strengthen the Medicinal Chemistry Discipline through the arrangement of conferences, seminars and other educational initiatives.

Mission

1972
276

Founded

Members

Trade & Industry: 70%
Research Institute: 1%
University: 19%
Other: 10%

Member profile

Postal address

Wallingatan 26A
SE-111 81 Stockholm Sweden

+46 8 723 50 00
+46 8 20 55 11

goran.lidgren@lakemedelsakademin.se
www.swepharm.se

Telephone
Fax

E-mail
Website

Activities

Symposia, seminars, courses.

Activities for 2008 will come up soon!

4th Anglo-Swedish Medicinal Chemistry Symposium •
(March 2009), Åre, Sweden

President

Secretary/Treasurer

EFMC-Delegate

Dr. Anders KARLÉN
(UPPSALA UNIVERSITY)

Anna-Lena GUSTAVSSON
(BIOVITRUM)

Dr. Anders KARLÉN
(UPPSALA UNIVERSITY)
### Division for Medicinal Chemistry (DMC), Swiss Chemical Society (SCS)

| **Mission** | The DMC provides a forum for scientists interested in medicinal chemistry and related fields by organising symposia, seminars, presentations and courses. |
| **Founded** | 1990 |
| **Members** | 605 |
| **Member profile** | Trade & Industry: 78%  
Research Institute: 3%  
University: 11%  
Other: 8% |
| **Postal address** | Schwarztorstrasse 9  
CH-3007 Bern Switzerland |
| **Telephone** | +41 31 310 40 90  
+41 31 310 40 29 |
| **Fax** | info@scg.ch  
www.scg.ch |
| **Activities** | • Minisymposium on «Drug Targeting» (May 29, 2008), Basel, Switzerland  
• Fall Meeting of the Swiss Chemical Society (September 11, 2008), Zürich, Switzerland  
• 8th Swiss Course on Medicinal Chemistry (October 12-17, 2008), Leysin, Switzerland |
| **President** | Dr. Hans Peter MAERKI  
(HOFFMANN-LA ROCHE AG) |
| **EFMC-Delegate** | Dr. Peter MOHR  
(HOFFMANN-LA ROCHE AG) |
Section of Pharmacochemistry, Royal Netherlands Chemical Society (KNCV)

To promote scientific research and education in the area of pharmacochemistry. To bring together scientists in the field and to offer them a platform for discussion and exchange of ideas. To identify talent in the field. To organise meetings in the field.

28th August 1970
400 (including student members)
Trade & Industry: 20%
Research Institute: 10%
University: 40%
Other: 30%

Dr. J.C.H.M. Wijkmans
N.V. Organon
Department of Medicinal Chemistry, Room RK 3111
P.O. Box 20
NL-5340 BH Oss The Netherlands
+31 412 665464
+31 412 662546
jac.wijkmans@organon.com
www.kncv.nl

Organisation of one annual scientific meeting (1 day).
Co-organisation of Dutch Medicine Days (FIGON) (2 days).
Co-organisation of annual NWO platform meeting (2 days).
Co-organisation of sessions at KNCV Winter/Summer Congress.
Participation in KNCV, NWO, FIGON and EFMC platforms.
Dutch Pharmacochemistry Award every 2 years for the best Dutch Ph.D. thesis in the field.

17th LACDR School on Medicinal Chemistry • (October 28-31, 2008), Noordwijkerhout, The Netherlands
Alzheimer Disease, Medicinal Chemistry symposium • (part of KNCV Spring Symposium)
(17 April 2008) Congrescentrum, De Reehorst, Ede, The Netherlands
28th Noordwijkerhout-Camerino-Cyprus Symposium on Trends in Drug Research (May 2009), Noordwijkerhout, The Netherlands

Prof. Dr. A.P. IJZERMAN
(MEDICINAL CHEMISTRY/LACDR)
Dr. J.C.H.M. WIJKMANS
(N.V. ORGANON)
Dr. H.K.A.C. COOLEN
(SOLVAY PHARMACEUTICALS BV)
Prof. Henk TIMMERMAN
(VRIJE UNIVERSITEIT LACDR)
### Mission
Establish communication and cooperation between the members. Establish policies in medicinal chemistry teaching and research in the country. Organise scientific meetings and conferences, get in touch with international related bodies.

### Founded
1994

### Members
170

### Member profile
Academics: 100%

### Postal address
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University TR-06330 Ankara, Turkey

### Telephone
+90 312 222 72 25
+90 312 223 50 18

### Fax

### E-mail
mfsahin@gazi.edu.tr

### Website
www.medchem.org

### Activities
Organising meetings and conferences.

### President
Prof. Dr. M. Fethi SAHIN
(GAZI UNIVERSITY)

### EFMC-Delegate
Prof. Dr. M. Fethi SAHIN
(GAZI UNIVERSITY)
The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC)

The BMCS aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules. It also acts to promote public awareness of the crucial role played by chemistry in the modern industrial environment.

1995 (Formerly Fine Chemicals & Medicinals Group)
1129 in total; 600 of whom are medicinal chemists
Predominantly industry

Royal Society of Chemistry - Burlington House - Piccadilly
GB-London W1J 0BA United Kingdom
+44 207 437 8656
+44 207 4937 8883
www.rsc.org/members/interestgroups/bmcs.index

Dr. David ALKER (DAVID ALKER ASSOCIATES)
Dr. Karl SWIFT (TOCRIS BIOSCIENCES)
Dr. Derek BUCKLE (DRB ASSOCIATES)

• The Challenges of Multi-Target Drug Discovery (March 10, 2008), London, UK
• 19th Symposium on Medicinal Chemistry in Eastern England (April 2008), Hatfield, UK
• Drugs from Natural Products IV (April 7-8, 2008), Cambridge, UK
• Pharmacokinetics and Drug Metabolism for Chemists (June 11, 2008), Liverpool, UK
• GPCRs in Medicinal Chemistry II (September 8-12, 2008), Gothenburg, Sweden
• 2nd Coast to Coast Meeting (October 26-29, 2008), Poole, UK
• 4th Anglo-Swedish Medicinal Chemistry Symposium (March 2009), Åre, Sweden
Society for Medicines Research

Mission
A multidisciplinary society with the object of advancing science relating to all aspects of medicines research, providing a common meeting ground for all those interested or involved in such research, and to further the education of such persons.

Founded
1966

Members
ca. 500

Member profile
Trade & Industry: 70%
Research Institute: 5%
University: 11%
Other: 4%

Postal address
840 Melton Road
GB-Thurmaston, Leicester, LE4 8BN, United Kingdom

Telephone
+44 116 269 1048
+44 116 264 0141

Fax

E-mail
secretariat@smr.org.uk

Website
www.smr.org.uk

Activities
The SMR organises four one-day scientific meetings per year in the UK.

Examples of meeting topics:
- Improving medicines through drug delivery;
- The role of sodium channels in disease;
- Case histories in drug discovery; Trends in medicinal chemistry

(More details are available on the SMR web site).

President
Dr. Alan PALMER
(Pharmidex Pharmaceutical Services Ltd)

EFMC-Delegate
Dr. Richard ARMER
(Oxagen Ltd)
Astrazeneca

1, place Louis Renault - 92844 Rueil-Malmaison
FRANCE

www.astrazeneca.fr

Tel: +33 1 41 29 40 00
Fax: +33 1 41 29 40 01
A major STM publisher of both subscription and open access journals, Bentham Science answers the information needs for the pharmaceutical, bio-medical and medical research communities. Leading journals include Current Drug Metabolism (Impact Factor 5.67), Current Cancer Drug Targets (Impact Factor 5.67), Current Pharmaceutical Design (Impact Factor 5.27) and Current Medicinal Chemistry (IF 5.20), the leading review journal in its field and endorsed by 7 Nobel Laureates.


Current Medicinal Chemistry (IF 5.20), the leading review journal in its field and endorsed by 7 Nobel Laureates.

For subscriptions contact subscriptions@bentham.org

Visit us online at www.bentham.org and www.bentham.org/open

A-B
B-C

BOROCHEM SAS

Immeuble Emergence - 7, rue Alfred Kastler - 14000 Caen
FRANCE

► Alexandre Bouillon, Chief Scientific Officer
Christine Le Borgne, Sales Manager
sales@borocchem.fr • www.borocchem.fr
Tel: +33 213 945 073 • Fax: +33 213 462 651

BoroChem efficiently delivers innovative and exclusive organoboron building blocks to organic and medicinal chemists from the biotech pharmaceutical, cosmetic and agrochemical industries.

Our offer includes rare and versatile boronic acids and esters, boro-amino acids, halogeno heterocyclic compounds and custom synthesis from mg to multi kilos quantities to support your R&D efforts.

BRECONHERRY LTD Lower Road Trading Estate GB LEDBURY HR8 2DH +44 1531 632 476
BREVETTI CEA SPA Via Del Commercio 28 (ZA) IT 36050 BOLOGNA +39 4 455 38 241
BRISTOL MYERS SQUIBB 345 Park Avenue US NEW YORK 10154 +1 212 546 4000
BRUKER DALTONIK GMBH Faehrenheitsstrasse 4 DE 28359 BREMEN +49 421 2206 200
BUCH LABORTECHNIK AG Meiergeiststrasse 40 CH 9230 FLAWIL +41 71 304 58 50
BURGMANN LEUCHTMITTELGESELLSCHAFT GMBH Neues Auerlacher Strasse 6-10 DE 62515 WOLFRATSHAUSEN +49 7172 82 82
C & S CONSULTANTS 3 rue Miram FR 67100 STRASBOURG +33 3 40 38 65
CADCENTRE INTERNATIONAL LTD High Cross Madingley Road GB CAMBRIDGE CB3 0HB +44 1223 355 655
CALEA PROCESS SOLUTIONS LTD Butts Pond Industrial Estate GB STURMINSTER NEWTON DT10 1AZ +44 1258 471 122
CAUPER LIFESCIENCES ZAC PARIS-NORD 13 rue de la Perdrix BP 40016 FR 95911 ROUSSET CHARLES DE GAULLE CEDEX +33 1 48 63 7135
CAMAG Sonnenastrasse 11 CH 4132 MUTTENZ +41 61 467 34 34
CAMBRIDGESOFT CORP 8 Signal Court, Swamis Road GB SWANNOE CB5 9AQ +44 1223 464090
CANONGATE TECHNOLOGY LTD 36 Inglis Green Road GB EDINBURGH EH14 2ER +44 131 557 2111
CAPSULIT SPA Via Lombarda 5 IT 20040 RONDOLINI MI +39 3 962 79 51
CARL-ZEISS Ikarosias 6 BE 1930 ZAVENTEM +32 2 716 38 11
CBIS LTD 11 Ark Royal Way Lakeside Technology Park GB BIRKENHEAD CH41 9HT +44 151 669 300
CEPHERFhouse of Panay FR 93720 FOZETTES +33 2 47 42 48 48
CECELL INSTRUMENT LTD Milton Technical Centre Milton GB CAMBRIDGE CB4 0AZ +44 1223 420 821
CELENA GENOMICS 45 West Gude Drive US ROCKVILLE, MD 20850 +1 240 463 3000
CELITE FRANCE SA 7, Rue du Stade FR 92745 MURAT +33 4 71 20 04 49
CELL THERAPEUTICS INC. 201 Elliot Ave. West, Suite 400 US SEATTLE, WA 98119 +1 206 213 6315
CEM CORP. PO BOX 200 IT 4002 FORMAZZO +39 44 794 4980
CEPHALON INC. 145 Brandwine Parkway US WEST CHESTER PA 19380 +1 610 738 6344
CEPIS 126 Rue Dairton FR 92306 FUEL-MALMASON CEDEX +33 (0)1 45 64 44 60
CEREX 87 Route de Seurre BOX BP 3 FR 21910 CORSELLES-LES- CITEAUX +33 2 60 70 71 11
CHARNWOOD MOLECULAR LTD The Heritage Building 7 Beaumont Court Prince William Road GB LOUGHBOROUGH LE11 5GA +44 (0)1509 23207

CHEMBRIDGE CORPORATION

16981 Via Tazon, Suite G - 92127 San Diego, California USA

sales@chembridge.com
www.chembridge.com
www.chembridgeresearch.com
Tel: +1 858 451 7400 • Fax: +1 858 451 7401

ChemBridge offers an extensive portfolio of advanced discovery chemistry products and contract research services, including over 700,000 drug-like, diverse, small molecule compound collections and diverse & targeted in-house parallel-synthesized screening libraries (200,000 cmps total), as well as customized discovery chemistry research services. ChemBridge Corporation together with ChemBridge Research Laboratories, Inc. (CRL) provide a comprehensive portfolio of efficient and cost-effective enabling chemistry solutions for all stages of small molecule drug discovery, from initial hit generation, to hit-to-lead, to lead optimization and preclinical candidate identification.
CHIRAL TECHNOLOGIES specializes in enantiomeric separation products and services for the pharmaceutical industries. The company assists customers throughout the drug development process, from initial synthesis to production of the finished product.

- DAICEL HPLC columns and bulk chiral stationary phases,
- Analytical method development
- Customers who do not have time or available facilities to produce single enantiomer compounds at the preparative or pilot plant scale can take advantage of the Custom Separation Service that utilizes chromatographic resolution technology. The facility complies with cGMP and GLP guidelines, and is available for separation of racemates.

### Directory of Companies

<table>
<thead>
<tr>
<th>Company</th>
<th>Address</th>
<th>Phone</th>
<th>Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHIRAL TECHNOLOGIES EUROPE</td>
<td>Boulevard Gonthier d’Andernach - BP 80140</td>
<td>4142</td>
<td>115961229</td>
</tr>
<tr>
<td>Chemistry Letters</td>
<td>Elsevier: Publishers of leading international Medicinal Chemistry research, including Bioorganic &amp; Medicinal Chemistry Letters, the 2nd highest cited journal in Medicinal Chemistry.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Producing and selling HTS compounds since 1995, Life Chemicals Inc. offers state-of-the-art and quality assured outsourcing: about 239,000 drug-like and lead-like compounds presented as template based libraries. Targeted libraries (Kinase, Protease, Ion Channel, Nuclear Receptor, GPCR), Building blocks, Custom synthesis projects. Excellent service, reasonable prices.

**LIFE CHEMICALS INC.**

2477 Glenwood School Drive, Suite 203
Burlington, Ontario, L7R 3R9
CANADA

Irina Chabanny, Director. Administration and Finance
lifechemicals@lifechemicals.com
www.lifechemicals.com
Telephone: +1(905)634-5212 - Fax: +1(905)634-4719

Life Chemicals Inc. offers state-of-the-art and quality assured outsourcing: about 239,000 drug-like and lead-like compounds presented as template based libraries. Targeted libraries (Kinase, Protease, Ion Channel, Nuclear Receptor, GPCR), Building blocks, Custom synthesis projects. Excellent service, reasonable prices.
Novartis is currently the fifth largest pharmaceutical company worldwide with about 75,000 employees. Novartis produces medicines in the areas of central nervous system drugs, cardiovascular drugs, anti-inflammatory and pain medicines, cancer drugs, immunosuppressive and dermatology agents.
P-Q

PROUS SCIENCE

Provenca, 388, 08025 Barcelona SPAIN

About Prous Science, a Thomson Scientific business

For more than 40 years, Prous Science has been a trusted source of information on which science depends to discover safer and more effective medicines. Prous Science products have evolved through the years from print journals to sophisticated electronic products incorporating the latest advances in IT. The business has complemented its drug discovery solutions with a series of key partnerships to widen the dissemination of medical education worldwide by fostering relationships with key medical associations and centers of excellence worldwide. Prous Science was acquired by Thomson Scientific, a leading information solutions provider, in September 2007. For more information visit www.prous.com and scientific.thomson.com.
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders and diseases of the central nervous system.

Small Molecules! Pyxis Discovery offers chemistry based lead discovery services to the global pharmaceutical industry with three major focuses: the development of Smart Libraries (lead-like molecules and fragments), a Proteases lead discovery service using a proprietary screening platform and a fragment based lead discovery service.
SCANNBECH LTD
44 Arkanight Road Astmoor Industrial Estate
GB
RUNGCORN WAT 1NU
+44 1928 561 747

SCHAEFF SYSTEM GMBH
Kramerstrasse 22 Baden-Wurttemberg
DE
+49 713 137 860

SCHENK PROCESS GMBH
Landwehrstrasse 55
DE
+49 613 1321 028

SCHERING AG
Mollerstr. 178
DE
BERLIN
+49-30-468-11 11

SCHERING PLOUGH INTERNATIONAL
2000 Galtzing Hill Road
US
KENLYWORTH NJ 07033-0530
+1 (909) 289-4000

SCHMETTERLING ASSOCIATES
11A Dawson Place
GB
LONDON W2 4TD
+44 20 7221 9599

SCHOTT GLAS
Hattenbergstrasse 10
DE
+49 613 1321 210

SCIENCE INTERNATIONAL
Batemans House 62-68 Hills Road
GB
CAMBRIDGE CB3 1QO
+44 1223 328 550

SCIENCE MARKETING INTERNATIONAL
Units 1 & 2The Standings Maisemore Court
GB
GLoucester GL2 8EY
+44 1452 310 210

SCIENTIFIC UPDATE
Maycroft Place Stone Cross Mayfield
GB
EAST SUSSEX TN20 6EW
+44 1435 873062

SCTEGIC UK
11 Hobbs Court Jacob Street
GB
LONDON SE1 2BG
+44 20 7394 3592

SELYNEVES
Post Office Box 12378 Research Triangle Park
US
+1 (908) 298-4000

SEAL LINE SPA
Via Bernande 11
IT
MONTEGALDELLA
+39 4 447 37 200

SENN CHEMICALS AG
Industriestrasse 12
CH
DIELSDORF
+41 1 954 90 54

SENSON TECHNOLOGY LTD
PO BOX 36
GB
NEWTOWNARDS BT23 4XQ
+44 1252 730 726

SEPHA LTD
Jubilee Road
GB
NEWTOWARDS BT23 4XQ
+44 2891 824 252

SEQUENOM
3985 John Hopkins Court
US
SAN DIEGO, CA 92121-1331
+1 658 202 9000

SERENDO INTERNATIONAL S.A.
15bis, chemin des Mines Case postale 54
CH
GENEVA 20
+41 22 730 2000

SERIEV
22 rue Garnier
FR
NEUILLY-SUR-SEINE CEDEX
+33 1 55 72 80 00

INSTITUT DE RECHERCHES SERVIER
3 rue de la Republique
F 92150 SURESNES
FRANCE
www.servier.fr

SETARAM SA
7 Rue de l’Ostatoire
FR
CAULIERE
+33 4 72 10 25 25

SHAW PACKAGING SERVICES
1 Privet Place
GB
GOSPORT PO12 3SG
+44 2392 583 256

SHIMADZU USA
4000 North 45th Way
US
SEATTLE, WA 98103-2600
+1 206 934 6000

SHIONOGI QUALICAPS SA
Calle de la Granja 49
ES
ALCOBENDAS /SÃO
+34 91 663 0800

SILVERSON MACHINES LTD
Waterside
GB
CHESHAM HP1 1RG
+44 1484 786 331

SIMPORT
Bernard Pon 288 Béneil
CA
QUEBEC JG 6G5
+1 450 464 1723

SINTOFARM SPA
Via Tagliati 5
IT
QUASTALLA
+39 5 228 31 321

SIRIUS ANALYTICAL INSTRUMENTS LTD
Riverside Forest Row Business Park
GB
FOREST ROW RH16 5DW SUSSEX
+44 1432 820 720

SLEEVER INTERNATIONAL
5 Avenue Arago Box BP 27
FR
MORANGIS
+33 1 69 74 75 76

SOLUTIA EUROPE
Rue Lard Burniat 3
BE
LOUVAIN-LA-NEUVE
+32 10 48 12 11

SPECS
Kluyverweg 6, NL-2629 HT, Delft
THE NETHERLANDS
info@specs.net
www.specs.net
Tel: +31 15 2518 111 - Fax: +31 15 2518 181

Specs is one of the leading suppliers of screening compounds, building blocks and natural products. We offer a wide range of services such as laboratory services, cheminformatics, compound sourcing and complete library management.
8,300 people in over 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing over pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune

**Contact Information**

**Tel:** +32 2 559 99 99 - **Fax:** +32 2 559 99 00

**Allée de la Recherche, 60 - 1070 Brussels**

**Website:** [www.ucb-group.com](http://www.ucb-group.com)
WYETH

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Magid Abou-Gharbia, Ph.D., Sr. VP, Chemical & Screening Sciences
www.wyeth.com
Tel: 732-274-4522 - Fax: 732-274-4500

Medicinal Chemistry in Europe - Yearbook 2008 is edited by:
EFMC offers any company the opportunity to become an official corporate sponsor. Corporate membership will help the EFMC with its objective of advancing the science of medicinal chemistry and can be achieved in several ways:

- by making a cash donation of at least 2500 Euros
- by sponsoring an official EFMC award
- by providing EFMC travel grants for attending the ISMC
- by sponsoring an EFMC international conference

Corporate Members will be acknowledged by the Federation in its primary literature and website, which will include their logo. In addition, a link to the company careers website will be included on the EFMC website free of charge. They will also be eligible for an expanded entry in the ‘Directory of Companies’ in the EFMC Yearbook “Medicinal Chemistry in Europe”, distributed to more than 6 500 medicinal chemists in Europe annually. Their nominee will also be invited to participate in round-table discussions organised during the biennial ISMC and can be proposed to join conference committees.

Anyone interested in their company becoming a Corporate Member should contact Dave Alker at davidalker@btinternet.com
Polish Society of Medicinal Chemistry

Basis for mutual contacts and integration for scientists who represent different profile of their activity in the following areas of medicinal chemistry: organic and bioorganic synthesis, analytical chemistry, computational chemistry, biochemistry, molecular biology, biotechnology, pharmacy and medicine.

Mission

Founded

Members

Postal address

Telephone

Fax

E-mail

Website

Activities

President

Vice-President

EFMC-Delegate

EFMC-Correspondent

Basis for mutual contacts and integration for scientists who represent different profile of their activity in the following areas of medicinal chemistry: organic and bioorganic synthesis, analytical chemistry, computational chemistry, biochemistry, molecular biology, biotechnology, pharmacy and medicine.

2006

50

Jagiellonian University

Medical College, Pharmacy Faculty

Medyczna 9

PL - 30-688 Kraków Poland

+48 12 657 04 88

+48 12 657 04 88

mfkonono@cyf.kr.edu.pl

www.ptchem.lodz.pl/en

Organization of occasional gatherings where various theoretical and practical topics of drug research and development are discussed.

Participation in organization of national and international conferences on medicinal chemistry.

Organization of the platform for exchange of ideas, news and informations on medicinal chemistry activities in the scientific society interested in this broad subject.

Prof. Janina KAROLAK-WOJCIECHOWSKA

Prof. Dariusz MATOSIUK

Prof. Katarzyna KIEC-KONONOWICZ (JAGIELLONIAN UNIVERSITY)

Prof. Katarzyna KIEC-KONONOWICZ

National Adhering Organisations